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Summary
Background.  —  The  rate  of  pacemaker  implantation  is  rising.  Given  that  the  life  expectancy
of the  population  is  projected  to  increase,  a  large  number  of  elderly  patients  are  likely  to
be implanted  in  the  future.  As  pacemaker  batteries  can  last  for  8—10  years,  an  increasing
number of  pacemaker  recipients  will  require  replacement  of  their  devices  when  they  become
nonagenarians.
Aims. —  To  analyse  the  short-  and  long-term  outcomes  after  device  replacement  in  nonagenar-
ians.
Methods. —  Patients  aged  ≥  90  years  referred  to  a  tertiary  centre  for  pacemaker  replacement
from January  2004  to  July  2014  were  included  retrospectively.  Clinical  follow-up  data  were
obtained from  clinical  visits  or  telephone  interviews  with  patients  or  their  families.  The  pri-
mary clinical  endpoint  was  total  mortality.  Secondary  endpoints  included  early  and  delayed
procedure-related  complications  and  predictive  risk  factors  for  total  mortality.
Abbreviations: AF, atrial ﬁbrillation; AV, atrioventricular; BMI, body mass index; CI, conﬁdence interval; CRT, cardiac resynchronization
therapy; CRT-P, cardiac resynchronization therapy-pacemaker; HR, hazard ratio.
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Results.  —  Sixty-two  patients  were  included  (mean  age  93.3  ±  2.9  years  at  time  of  pace-
maker replacement).  Mean  procedure  duration  was  35.7  ±  17.2  minutes.  Mean  hospital  stay
was 2.2  ±  1.1  days.  One  patient  died  from  a  perioperative  complication.  Thirty-seven  patients
(59.7%) died  during  a  median  follow-up  of  22.1  months  (interquartile  range,  11.8—39.8  months).
Survival rates  were  84.2%  (95%  conﬁdence  interval  [CI]  71.8—91.5%)  at  1  year,  66.9%  (95%  CI
51.8—78.2%)  at  2  years  and  22.7%  (95%  CI  10.6—37.7%)  at  5  years.  Atrial  ﬁbrillation  (hazard
ratio 2.47,  95%  CI  1.1—5.6)  and  non-physiological  pacing  (i.e.  VVI  pacing  in  patients  in  sinus
rhythm)  (hazard  ratio  2.20,  95%  CI  1.0—4.9)  were  predictors  of  mortality.
Conclusions.  —  Pacemaker  replacement  in  nonagenarians  is  a  safe  and  straightforward  pro-
cedure. These  data  suggest  that  procedures  can  be  performed  securely  in  this  old  and  frail
population,  with  patients  living  for  a  median  of  30  months  afterwards.
© 2015  Elsevier  Masson  SAS.  All  rights  reserved.
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Résumé
Contexte.  —  Le  taux  d’implantation  de  stimulateurs  cardiaques  est  en  croissance  constante.
L’espérance  de  vie  augmentant,  de  nombreuses  personnes  âgées  seront  implantées  dans  le
futur. L’autonomie  des  batteries  des  stimulateurs  étant  de  8  à  10  ans,  de  nombreux  patients
nécessiteront  le  remplacement  de  leur  appareil  à  >  90  ans.
Buts. — Étudier  le  devenir  à  court  et  à  long  terme  des  nonagénaires  après  remplacement  de
leur stimulateur  cardiaque.
Méthodes.  — Tous  les  patients  nonagénaires  adressés  pour  un  changement  de  stimulateur  car-
diaque entre  janvier  2004  et  juillet  2014  ont  été  inclus  de  fac¸on  rétrospective.  Les  données
cliniques  étaient  obtenues  lors  des  consultations  de  suivi  ou  par  téléphone  auprès  des  patients
ou de  leurs  familles.  Le  critère  primaire  de  jugement  était  la  mortalité  toutes  causes.  Les
critères secondaires  comprenaient  les  complications  immédiates  et  à  long  terme,  ainsi  que  les
facteurs prédictifs  de  mortalité  toutes  causes.
Résultats.  — Soixante-deux  patients  ont  été  inclus  (93,3  ±  2,9  ans,  durée  de  procédure
35,7 ±  17,2  minutes).  Un  patient  est  décédé  d’une  complication  périopératoire.  Durant  le  suivi,
37 patients  (59,7  %)  sont  décédés.  Le  taux  de  survie  était  respectivement  de  84,2  %  (IC  95  %
71,8—91,5 %),  66,9  %  (IC  95  %  51,8—78,2  %)  et  22,7  %  (IC  95  %  10,6—37,7  %)  après  1,  2  et  5  ans.
La ﬁbrillation  atriale  (HR  2,47,  IC  95  %  1,1—5,6)  et  la  stimulation  cardiaque  non  physiologique
(mode VVI  chez  les  patients  en  rythme  sinusal)  (HR  2,20,  IC  95  %  1,0—4,9)  étaient  des  facteurs
prédictifs indépendants  de  mortalité.
Conclusions.  —  Le  remplacement  de  stimulateurs  cardiaques  est  une  procédure  simple  pouvant
être réalisée  sans  risques  majeurs  chez  les  nonagénaires.  Après  la  procédure,  la  survie  médiane
est de  30  mois.
© 2015  Elsevier  Masson  SAS.  Tous  droits  réservés.
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n  Europe,  933  pacemakers  per  million  inhabitants  are
mplanted  every  year  [1].  The  implantation  rate  is  ris-
ng  continuously,  partly  because  of  the  ageing  of  general
opulation,  resulting  in  an  increased  risk  of  developing
trioventricular  (AV)  block  and  sinus  node  dysfunction,  but
lso  related  to  the  expansion  of  indications  for  cardiac
esynchronization  therapy  (CRT).  The  average  age  at  device
mplantation  is  currently  80  years  [2].
In  2012,  life  expectancy  in  Europe  was  80.3  years  for
he  general  population  (83.1  years  for  women;  77.5  years
or  men),  a  2.6-year  increase  since  2002  [3].  By  2060,  life
xpectancy  is  projected  to  be  89.1  years  for  women  and
4.6  years  for  men  [4].  A  163.4%  increase  in  the  number  of
s
m
t
iatients  aged  ≥  80  years  is  expected.  To  date,  only  a  few
tudies  have  speciﬁcally  reported  the  long-term  outcome  of
ery  elderly  patients  implanted  with  a  cardiac  pacemaker.
n  a recent  study,  Udo  et  al.  evaluated  the  outcome  of  pace-
aker  recipients  aged  >  80  years,  and  reported  a  cumulative
-year  survival  of  around  50%  after  implantation,  with  a
omplication  rate  of  18.1%  [5].
As  pacemaker  batteries  can  last  for  as  long  as  8—10  years,
n  increasing  number  of  pacemaker  recipients  will  probably
equire  replacement  of  their  devices  when  they  are  nonage-
arians.  No  studies  speciﬁcally  reporting  the  outcome  and
urvival  of  nonagenarians  referred  for  pacemaker  replace-
ent  have  been  published.  Therefore,  we  aimed  to  analyse
he  short-  and  long-term  outcomes  after  device  replacement
n  these  very  elderly  patients.  Procedural  characteristics,
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survival  rate  and  causes  of  deaths  were  analysed  in  the
present  study.
Methods
Study population
The  present  study  is  based  on  a  retrospective  analysis  of  all
consecutive  patients  aged  >  90  years  referred  to  our  tertiary
centre  for  device  replacement  from  January  2004  to  July
2014.
Clinical  information  was  obtained  from  the  patients’
medical  records,  which  included  patient  demographics,
medical  history,  medication  use  and  history  of  pacing  (indi-
cation  of  pacing,  age  at  primary  implantation,  device  type
and  number  of  replacements).  ‘‘Physiological  pacing’’  was
deﬁned  as  the  implantation  of  a  dual-chamber  pacemaker
or  CRT-pacemaker  (CRT-P)  in  patients  in  sinus  rhythm  and
a  single-chamber  pacemaker  in  patients  in  atrial  ﬁbrillation
(AF),  while  ‘‘non-physiological  pacing’’  was  deﬁned  as  the
implantation  of  a  VVI  chamber  device  in  patients  in  sinus
rhythm.  The  Charlson  Co-morbidity  Index,  a  validated  score
to  assess  patients’  co-morbidities,  was  evaluated  using  dedi-
cated  scales  available  online  [6,7].  Various  Charlson  indexes
have  been  proposed,  depending  on  the  number  of  variables
included.  We  decided,  as  previously  performed  by  Mandawat
et  al.  in  their  study  of  octogenarian  and  nonagenarian  pace-
maker  recipients,  to  use  the  index  that  does  not  include  age,
as  all  our  patients  were  ≥  90  years  [8].
The  procedural  characteristics  of  the  device  replacement
were  recorded,  including  the  type  of  pacemaker  implanted,
duration  of  hospital  stay  and  procedural  complications.
Follow-up and outcomes
Clinical  follow-up  data  were  obtained  from  clinical  visits  or
telephone  interviews  with  patients  or  their  families,  gen-
eral  practitioners  or  nurses.  The  primary  clinical  endpoint
was  total  mortality  over  the  follow-up  period  (censor  date
1  August  2014).
Causes  of  death  were  obtained  through  hospital  dis-
charge  notes  and  inquiries  made  with  the  family,  the  general
practitioner  or  nursing  homes,  and  were  classiﬁed  using
the  International  Statistical  Classiﬁcation  of  Diseases  and
Related  Health  Problems  classiﬁcation  (ICD-10),  as  car-
diovascular  cause  (I00-I99),  pulmonary  cause  (J00-J99),
neoplastic  cause  (C00-D48),  renal  cause  (N00-N99),  caused
by  multiple  organ  dysfunction  (R65-10)  or  of  unknown  origin
(R99).  Deaths  were  classiﬁed  as  unknown  when  no  speciﬁc
cause  could  be  identiﬁed.  Patients  lost  to  follow-up  were
censored  as  alive  on  the  day  of  the  last  visit.
Secondary  endpoints  included  early  and  delayed
procedure-related  complications  and  predictive  risk  factors
for  death.
Statistical analysesData  are  summarized  as  frequencies  and  percentages  for
categorical  variables.  Quantitative  variables  are  expressed
as  means  ±  standard  deviations.  Qualitative  data  were  com-
pared  using  Fisher’s  exact  test,  while  quantitative  data  were
o
t
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ompared  using  the  Mann—Whitney  test.  Survival  curves
ere  estimated  using  Kaplan—Meier  method,  with  log-rank
ests  for  comparisons.  The  prognostic  relevance  of  different
haracteristics  to  long-term  survival  was  assessed  in  uni-
ariate  and  multivariable  fashion  using  Cox’s  proportional
azards  regression  analysis.  In  addition  to  age  and  sex,  all
alues  with  P  ≤  0.2  in  the  univariate  analysis  were  used  for
he  multivariable  analysis.  All  tests  were  two-sided  at  the
.05  signiﬁcance  level.  All  statistical  analyses  were  carried
ut  using  SPSS  for  Windows,  version  16.0  (SPSS  Inc.,  Chicago,
L,  USA).
esults
tudy population
rom  January  2004  to  July  2014,  62  nonagenarian  patients
ere  referred  for  pacemaker  replacement.  Patient  char-
cteristics  are  described  in  Table  1.  The  mean  age
as  93.3  ±  2.9  years  at  the  time  of  replacement  (range,
0—104  years)  and  50%  were  men.  Most  patients  were  living
t  home  (36  patients,  58.1%).
The  mean  age  at  ﬁrst  implantation  was  81.9  ±  7.7  years
range,  53—95  years).  Therefore,  the  mean  delay  between
rst  implantation  and  study  inclusion  was  11.4  ±  6.8  years.
or  most  patients  (52  patients,  83.9%)  this  was  the  ﬁrst
evice  replacement,  while  eight  patients  had  already  had
ne  replacement  and  two  patients  had  undergone  two
eplacements.
The  main  indications  at  ﬁrst  implantation  were  high
egree  AV  block  (63.0%)  and  sinus  node  dysfunction  (22.6%).
ccordingly,  most  patients  had  a dual-chamber  pacemaker
mplanted  during  the  ﬁrst  procedure  (45  patients,  72.6%)
nd  pacing  was  considered  as  ‘‘physiological’’  for  79.0%.
Device  replacement  was  elective  for  most  patients.  How-
ver,  two  patients  were  hospitalized  for  acute  heart  failure
econdary  to  AV  block,  the  device  having  reached  the  elec-
ive  replacement  index.
rocedural characteristics and short-term
utcome
rocedures  were  straightforward,  lasting  for  an  average  of
5.7  ±  17.2  minutes,  and  were  performed  with  local  anaes-
hesia  using  mild  sedation.  The  mean  hospital  stay  was
.2  ±  1.1  days  (range,  1—8  days).  Only  two  patients  had  out-
atient  surgeries.
Among  the  44  patients  with  a  previously  implanted
ual-chamber  pacemaker,  12  (27.3%)  were  in  persistent  or
ermanent  AF  at  the  time  of  replacement  and  were  down-
raded  to  a  single-chamber  device.  One  patient  initially
mplanted  for  paroxysmal  AV  block  with  a  single-chamber
acemaker  was  upgraded  to  a  CRT-P  device  for  overt  heart
ailure  symptoms  due  to  left  ventricular  dysfunction.  All
atients  previously  implanted  with  CRT-P  devices  were
ffered  the  same  device  at  the  time  of  replacement.
At  the  time  of  device  replacement,  many  patients  were
n  a  regimen  of  anticoagulant  (19.3%)  or  antiplatelet  (51.6%)
herapies;  the  mean  number  of  drugs  was  5.4  ±  3.2.
One  patient  had  transient  confusion  after  the  procedure.
he  two  patients  not  scheduled  for  surgery  and  who  were
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Table  1  Patient  characteristics  (n  =  62).
Data  at  the  time  of  ﬁrst
implantation
Men  31  (50.0)
Age  at  ﬁrst  implantation  (years)  81.9  ±  7.7  (53—95)
Indication  for  ﬁrst  implantation
High  degree  AV  block  39  (63.0)
Sinus  node  dysfunction  14  (22.6)
High  rate  AF  with  AV  junction
ablation
3 (4.8)
Carotid  sinus  hypersensitivity  3  (4.8)
CRT-P  for  heart  failure 2  (3.2)
Hypertrophic  cardiomyopathy 1  (1.6)
Type  of  device  before
replacement
Single-chamber  15  (24.2)
Dual-chamber  45  (72.6)
CRT-P 2  (3.2)
Data  at  the  time  of  device
replacement
Age  (years) 93.3  ±  2.9  (90—104)
BMI  (kg/m2) 24.1  ±  4.0
Time  from  ﬁrst  implantation  to
replacement  (years)
11.4  ±  6.8
Heart  rhythm  at  the  time  of
replacement
Sinus  rhythm  45  (72.5)
Persistent/permanent  AF  17  (27.5)
Type  of  device  after
replacement
Single-chamber  27  (43.5)
Dual-chamber  32  (51.6)
CRT-P  3  (4.9)
Co-morbidities
Cardiac  surgery  4  (6.5)
Coronary  artery  disease  11  (17.7)
Diabetes  mellitus  4  (6.5)
Heart  failure  28  (45.2)
History  of  AF  32  (51.6)
History  of  stroke  5  (8.1)
Hypertension  33  (53.2)
Valvular  disease  18  (29.0)
Charlson  Co-morbidity  Index  1.5  ±  1.1
Treatments
Anticoagulants  12  (19.3)
Antiplatelets  32  (51.6)
Number  of  medications 5.4  ±  3.2
Blood  work
Haemoglobin  concentration
(g/dL)
13.1  ±  1.4
Creatinine  concentration
(mol/L)
109.1  ±  35.4
Patients  living  in  nursing  homes  26  (41.9)
Physiological  stimulation  49  (79.0)
Data are expressed as number (%) or mean ± standard devi-
ation (range); AF: atrial ﬁbrillation; AV: atrioventricular;
BMI: body mass index; CRT-P: cardiac resynchronization
therapy-pacemaker.
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pigure 1. Survival of nonagenarians after pacemaker replace-
ent.
ospitalized  for  heart  failure  after  reaching  the  elective
eplacement  indicator  improved  after  medical  treatment.
o  signiﬁcant  haematoma  requiring  surgical  evacuation
ccurred,  including  in  patients  receiving  anticoagulant  or
ntiplatelet  drugs.  Aspiration  pneumonia  occurred  in  a  97-
ear-old  woman  during  the  procedure,  complicated  by  acute
espiratory  distress  syndrome,  leading  to  the  patient’s  death
 few  hours  later.
ong-term follow-up
he  median  duration  of  follow-up  was  22.1  months
interquartile  range,  11.8—39.8  months).  Seven  patients
11.3%)  were  lost  to  follow-up  and  were  censored  as  alive
n  the  day  of  the  last  visit.  During  follow-up,  no  patient  had
 pacemaker-related  infection  or  a  device/lead  dysfunction
equiring  a  redo  intervention.
Thirty-seven  patients  (59.7%)  died.  The  median  survival
ime  was  30.2  months  (2.5  years,  95%  conﬁdence  interval
CI]  26.2—41.8  months)  and  none  of  the  patients  lived  for
ore  than  7  years.  The  survival  curve  of  the  population  is
hown  in  Fig.  1.  Survival  rates  at  1,  2  and  5  years  were  84.2%
95%  CI  71.8—91.5%),  66.9%  (95%  CI  51.8—78.2%)  and  22.7%
95%  CI  10.6—37.7%),  respectively.  Fifteen  patients  (40.5%)
ied  from  a  cardiovascular  cause,  mainly  of  heart  failure
Table  2).  Despite  inquiries  made  with  the  general  practi-
ioner  or  medical  service  (in  the  case  of  patients  living  in
ursing  homes),  the  cause  of  death  remained  unknown  in  13
atients  (35.1%).
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Table  2  Mortality  and  causes  of  deaths  during  follow-
up.
Deaths  37  (59.7)
Cause  of  death
Cardiovascular  15  (40.5)
Unknown  13  (35.1)
Pulmonary  5  (13.5)
Neoplastic  2  (5.4)
Renal  failure  1  (2.7)
Multiple  organ  dysfunction  syndrome  1  (2.7)
Figure 2. Survival depending on pacing mode, after remov-
ing cardiac resynchronization therapy-pacemaker recipients (three
p
•Data are expressed as number (%).
Predictors of mortality
Predictors  of  all-cause  mortality  in  univariate  and  multivari-
able  analyses  are  shown  in  Table  3.  Although  not  signiﬁcant,
there  was  a  trend  (P  =  0.06)  towards  increased  mortality
risk  depending  on  initial  pacing  indication  (hazard  ratio
[HR]  1.23,  95%  CI  0.99—1.52),  non-physiological  pacing  (HR
2.06,  95%  CI  0.95—4.40)  and  longer  hospital  duration  (HR
1.35,  95%  CI  0.99—1.84).  In  the  multivariable  analysis,  AF
at  the  time  of  replacement  (HR  2.47,  95%  CI  1.1—5.6)  and
non-physiological  pacing  (HR  2.20,  95%  CI  1.0—4.9)  were  pre-
dictors  of  mortality.  Neither  co-morbidities  nor  the  Charlson
Co-morbidity  Index  were  predictors  of  mortality.
A  signiﬁcant  difference  in  survival  rates  was  observed
between  DDD  and  VVI  recipients  (median  41.3  months,  95%
CI  26.6—50.01  and  median  26.5  months,  95%  CI  13.4—38.2,
respectively;  log-rank  P  =  0.049,  Fig.  2).
DiscussionThe  main  ﬁndings  in  this  study  were  the  following:
• pacemaker  replacement  is  a  safe  procedure  in  nonagenar-
ians,  with  rare  perioperative  complications;
•
Table  3  Cox  regression  for  all-cause  mortality  in  pacemaker  
Univariate  analysis  
HR  (95%  CI)  
Age  (per  1-year  increase)  1.05  (0.93—1.20) 
History  of  atrial  ﬁbrillation  1.25  (0.63—2.46) 
History  of  stroke  2.34  (0.80—6.84) 
History  of  heart  failure  1.06  (0.54—2.09) 
History  of  cardiac  surgery  1.16  (0.35—3.82) 
Diabetes  0.48  (0.11—2.10) 
Atrial  ﬁbrillation  1.70  (0.80—3.63) 
Pacing  indication  1.23  (0.99—1.52) 
Pacing  mode  (VVI/DDD/CRT-P)  0.64  (0.34—1.22) 
Non-physiological  pacing  2.06  (0.95—4.40) 
Hospitalization  duration  1.35  (0.99—1.84) 
Number  of  treatments  1.03  (0.94—1.13) 
Charlson  Co-morbidity  Index  1.23  (0.87—1.72) 
CI: conﬁdence interval; CRT-P: cardiac resynchronization therapy-paceatients).
one  third  of  patients  in  sinus  rhythm  at  initial  implantation
are  in  AF  at  the  time  of  device  replacement,  allowing
downgrading  of  the  pacing  mode;
median  survival  after  replacement  is  30  months
(2.5  years);
recipients  aged  ≥  90  years.
Multivariable  analysis
P  HR  (95%  CI)  P
0.42
0.52
0.12  0.30  (0.04—2.50) 0.26
0.87
0.81
0.33
0.17  2.47  (1.10—5.60) 0.03
0.06  1.20  (0.95—1.51) 0.12
0.18  0.13  (0.01—1.47) 0.10
0.06  2.20  (1.00—4.90) 0.04
0.06  1.38  (0.99—1.94) 0.06
0.55
0.23
maker; HR: hazard ratio.
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AF  and  the  absence  of  physiological  pacing  are  predictors
of  mortality,  highlighting  that  fact  that  DDD  recipients  in
sinus  rhythm  at  the  time  of  replacement  should  be  offered
the  same  type  of  device.
To  date,  no  studies  have  reported  speciﬁcally  on  pro-
edural  safety  and  long-term  outcomes  after  pacemaker
eplacement  in  nonagenarians,  a  particularly  frail  popula-
ion.  The  percentage  of  the  population  aged  >  90  years  is
xpected  to  increase  in  the  next  decades.  According  to  the
merican  Social  Security  Administration,  one  of  every  four
eople  aged  65  years  today  will  live  past  the  age  of  90  years,
nd  one  of  10  people  will  live  past  95  years  [9]. Accordingly,
any  patients  currently  implanted  with  a  pacemaker  will
equire  device  replacement  when  they  are  nonagenarians.
rocedural safety
any  complications  can  occur  after  pacemaker  implanta-
ion,  such  as  haematoma,  device-related  infection,  lead
islodgment  or  device  extrusion.  These  complications  affect
pproximately  up  to  9.5%  of  device  recipients  [10]. Women,
nderweight  patients,  low-volume  centres  and  operators,
ual-chamber  devices,  upgrading  or  lead  revision  and  emer-
ency  out-of-hours  procedures  have  been  associated  with  a
igher  risk  of  complications  [10].  In  patients  aged  >  80  years,
do  et  al.  reported  signiﬁcant  complication  rates,  mostly
ead-related,  of  9.8%  within  2  months  and  6.9%  during
ong-term  follow-up;  these  rates  were  not  different  to
hose  in  patients  aged  <  80  years  [5].  Similarly,  very  elderly
atients  did  not  seem  to  have  more  complications  than
ounger  patients  in  other  studies  [11,12]. However,  in  the
argest  epidemiological  study  published  so  far  on  pacemaker
mplantations,  in  the  nonagenarian  subgroup,  including
ore  than  12,000  patients  from  the  Healthcare  Cost  and
tilization  Project  Nationwide  Inpatient  Sample  adminis-
rative  database,  Mandawat  et  al.  demonstrated  mortality
nd  complication  rates  of  1.87%  and  6.31%,  respectively,
hich  were  modestly  but  signiﬁcantly  higher  than  those  in
eptuagenarians  and  octogenarians  [8].  These  frail  patients
lso  had  a  signiﬁcantly  longer  hospital  stay  (4.27  days)  than
ounger  patients,  at  an  estimated  cost  of  >  $41,000.  Severe
o-morbidities  and  older  age  were  strong  predictors  of  mor-
ality.
Generator  change,  although  apparently  a  simple  pro-
edure,  also  has  a  high  risk  of  complications,  as  up
o  6.5%  of  patients  can  have  adverse  outcomes  [13,14].
hese  complications,  mainly  related  to  skin  erosion  and
ocket  infections,  are  inﬂuenced  by  operator  experi-
nce,  procedure  duration  and  device  type.  The  risk  of
nfection  was  shown  to  be  more  frequent  in  case  of
on-infectious  complications  requiring  redo  procedures.
n  the  REPLACE  registry,  authors  prospectively  assessed
rocedural-related  complications  associated  with  elec-
ive  pacemaker  or  implantable  cardioverter-deﬁbrillator
evice  replacements  over  6  months  of  follow-up.  Major
omplications  occurred  more  frequently  in  patients  needing
aterial  revisions,  supporting  careful  decision-making  when
enerator  replacement  is  needed  [15].  In  our  study,  only  one
ajor  complication  occurred  (an  aspiration  pneumonia  dur-
ng  surgery  leading  to  the  patient’s  death  the  same  day).  No
aematoma,  pocket  infection  or  lead-related  complications
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ere  noted  during  the  follow-up  period.  Only  one  patient
ad  transient  confusion  after  the  procedure.  Outpatient  pro-
edures  were  performed  in  two  patients  in  our  series,  and
ay  be  a good  choice  for  elderly  patients,  especially  those
iving  in  nursing  homes.  However,  many  of  these  patients  are
n  anticoagulant  or  antiplatelet  therapies,  and  close  moni-
oring  of  local  complications  (swelling,  haematoma)  may  be
ecessary  to  avoid  later  serious  adverse  events.
acing mode and outcome
s  the  mean  age  at  ﬁrst  implantation  was  81.9  ±  7.7  years
nd  the  patients  were  mostly  in  sinus  rhythm,  a  large  number
f  patients  (n  =  44)  had  had  atrial-based  devices  implanted
reviously.  The  optimal  pacing  mode  has  been  a matter  of
ebate  for  some  time.  In  2005,  the  United  Kingdom  Pac-
ng  and  Cardiovascular  Events  (UKPACE)  study  showed  that
n  elderly  patients  with  high  degree  AV  block,  the  pacing
ode  (VVI  or  DDD)  did  not  inﬂuence  the  rate  of  deaths
rom  all  causes  and  the  incidence  of  cardiovascular  events
16]. Healey  et  al.  published  a  meta-analysis  about  pac-
ng  modes  to  analyse  whether  an  atrial-based  pacing  mode
as  associated  with  better  long-term  outcomes  in  device
ecipients,  which  included  UKPACE  [16]  and  four  large  stud-
es  (CTOPP  [17], MOST  [18],  PASE  [19]  and  the  Danish  trial
20,21]).  The  authors  showed  that,  compared  with  ventricu-
ar  pacing,  the  use  of  atrial-based  pacing  does  not  improve
urvival  or  reduce  rates  of  heart  failure  or  cardiovascular
eath.  However,  physiological  pacing  was  shown  to  reduce
he  incidence  of  AF  (HR  0.8,  95%  CI  0.72—0.89;  P  =  0.00003)
nd  to  slightly  reduce  the  incidence  of  stroke  (HR  0.81,
5%  CI  0.67—0.99;  P  =  0.035)  [22].  However,  in  the  ﬁve  tri-
ls  in  this  meta-analysis,  the  average  age  of  the  patients
ncluded  was  approximately  72—80  years  [17—21,23].  In  very
lderly  patients  (≥  80  years),  mode  of  pacing  was  not  found
o  be  a  predictor  of  all-cause  mortality  [24], and  no  detri-
ental  effect  of  VVI  pacing  on  cognitive  function  was
emonstrated  [25].  In  our  study,  among  the  44  patients
nitially  in  sinus  rhythm  and  implanted  with  dual-chamber
evices,  12  patients  (27.3%)  were  in  permanent  AF  at  the
ime  of  device  replacement  and  were  downgraded  to  single-
hamber  devices.  The  remaining  patients  were  offered  a
eplacement  with  a  dual-chamber  pacemaker,  although  one
ay  argue  that  the  cost  difference  between  these  devices
approximately  D  500)  and  the  uncertain  clinical  beneﬁt
ay  advocate  the  systematic  replacement  of  dual-chamber
acemakers  with  single-chamber  devices  in  nonagenarians
n  sinus  rhythm.  However,  as  demonstrated  in  our  study,  AF
nd  non-physiological  pacing  were  predictors  of  mortality,
ith  HRs  of  2.47  and  2.20,  respectively.  These  data  suggest
hat  dual-chamber  pacemakers  in  patients  in  sinus  rhythm
hould  be  replaced  with  the  same  type  of  device  and  not  be
owngraded  to  a  single-chamber  device.
ong-term survival
uring  follow-up,  none  of  the  patients  needed  a  redo  pro-
edure  for  device/lead  failure  or  haematoma.  No  pocket  or
ead  infections  occurred.  Among  the  study  population,  37
atients  (59.7%)  died,  mainly  from  unknown  or  cardiovas-
ular  causes,  and  survival  rates  were  84.2%  at  1  year,  66.9%
t  2  years  and  22.7%  at  5  years;  the  median  survival  time
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was  30.2  months.  These  mortality  rates  are  similar  to  those
described  previously  by  Udo  et  al.  in  a  population  of  octoge-
narians  and  nonagenarians  implanted  for  the  ﬁrst  time  (86%,
75%  and  49%  after  1,  2  and  5  years  [5]),  and  in  nonagenarian
non-recipients  of  pacemakers  [26].
In  a  prospective  community-based  study,  Formiga  et  al.
found  that  better  cognitive  status  and  fewer  co-morbidities
(evaluated  by  the  Charlson  Co-morbidity  Index)  were  the
best  predictors  for  identifying  which  nonagenarians  will  die
after  a  5-year  follow-up  period  [26],  although  this  was  not
found  in  our  study.
Study limitations
We  acknowledge  some  limitations  in  our  study.  Our  analy-
sis  was  performed  as  a  retrospective  review  of  a  cohort  of
patients,  with  the  inherent  limitations  of  such  studies  (i.e.
some  patients  were  lost  to  follow-up).  Furthermore,  the
limited  number  of  patients  does  not  allow  precise  deter-
mination  of  predictive  factors  of  mortality.  Lastly,  despite
inquiries  made  with  the  general  practitioner  or  medical
service  (in  case  of  nursing  homes),  the  cause  of  death
remained  unknown  in  13  patients  (35.1%),  in  whom  the
devices  were  not  interrogated  post  mortem.
Conclusions
Pacemaker  replacement  in  nonagenarians  is  a  safe  and
straightforward  procedure,  with  rare  complications  occur-
ring  during  hospitalization.  This  procedure  can  be  performed
securely  in  this  old  and  frail  population,  and  is  useful  for  a
signiﬁcant  period  of  time,  with  patients  living  for  a  median
of  2.5  years  afterwards.  One  third  of  patients  in  sinus  rhythm
at  initial  implantation  are  in  AF  at  the  time  of  device
replacement,  allowing  downgrading  of  the  pacing  mode.
However,  for  patients  in  sinus  rhythm  at  the  time  of  replace-
ment,  a  dual-chamber  pacemaker  should  be  proposed,  as
non-physiological  pacing  seems  to  be  a  predictor  of  mortal-
ity.
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